LEADER 02227nam 2200373 450 001 9910765893403321 005 20230219032937.0 010 $a3-03897-339-4 035 $a(CKB)5400000000000539 035 $a(NjHacI)995400000000000539 035 $a(EXLCZ)995400000000000539 100 $a20230219d2018 uy 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aLung diseases $echronic respiratory infections /$fedited by Francesco B. Blasi 210 1$aBasel, Switzerland :$cMDPI,$d[2018] 210 4$dİ2018 215 $a1 online resource (216 pages) $cillustrations 320 $aIncludes bibliographical references. 330 $aBoth chronic and acute infections play a significant role in the pathogenesis and clinical course of chronic obstructive pulmonary disease (COPD) and both cystic fibrosis (CF) and non-CF bronchiectasis. There is also specific evidence that chronic infection, even in the absence of acute infection, has an influence on the manifestations and disease course. The infections found in COPD, CF, and bronchiectasis share a number of clinical similarities, the most striking of which are bacterial persistence despite the use of antibiotics and antibiotic resistance. In the last two decades, the rate of antibiotic resistance has increased dramatically and poses serious threats for patients and public health. There are different reasons for this increase in resistance, but the overuse of antibiotics in the community is certainly the most prominent. On the other hand, the chronic use of antibiotics in chronic diseases like COPD, CF, and bronchiectasis is also potentially associated with an increase in MDR pathogens. During the last decade, a growing interest has been raised in evaluating nontuberculous mycobacteria's role in chronic respiratory diseases like bronchiectasis. 517 $aLung Diseases 606 $aLungs$xDiseases 615 0$aLungs$xDiseases. 676 $a616.24 702 $aBlasi$b Francesco B. 801 0$bNjHacI 801 1$bNjHacl 906 $aBOOK 912 $a9910765893403321 996 $aLung diseases$93016270 997 $aUNINA